SCHEMBL184788

SCHEMBL184788

CC(C)Oc1ccc2nc(N)sc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.53
PIK3CA P42336 5/20 0.53
PIK3CB P42338 5/20 0.53
PI4KA P42356 5/20 0.53
PIK3CG P48736 5/20 0.53
PI4KB Q9UBF8 5/20 0.53
PIP5K1C O60331 2/20 0.43
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
SCN4A P35499 1/20 0.41
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
MAPT P10636 2/20 0.38
ACACB O00763 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558785 0.83 RAB9A (0.39) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL31456645 0.83 RAB9A (0.39) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL30189832 0.81 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL184747 0.81 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL30526543 0.77 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL184566 0.77 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19939687 0.74 SMN1; SMN2 (0.49) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL30526584 0.73 PIK3CA (0.57) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL21186282 0.72 NPC1 (0.55) PIK3CAPI4KAPI4KBRAB9ANPC1
SCHEMBL2666814 0.71 PI4KA (0.58) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
WO-2011095997-A1 BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2011-08-11 WO disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA PIK3CD 1948/4885PIK3CA 1151/4885PIK3CB 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.